Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Trial data on epcoritamab plus rituximab-lenalidomide, a novel CELMoD agent, late-line CAR-T cell therapy, and selecting ...

Drs Harrington and Gibson’s annual review of cardiovascular medicine: ACS guidelines, antiplatelet management, GLP-1s, and ...

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...

Dr Kami Maddocks reflects on fresh data, such as the new epcoritamab combo approval, evolving CD19 sequencing data, and ...

Insights from ASH 2025, including anticipated presentations, key takeaways, and how emerging research in paroxysmal nocturnal ...

The progress in understanding the pathophysiology of hidradenitis suppurativa appears to be leading to treatment strategies ...

Edward S. Cooper, MD, the American Heart Association’s first Black president, leaves behind an indelible mark on stroke ...

Growth hormone replacement therapy improves physical fitness, lifestyle habits, and quality of life in children with growth ...

When a parent’s health declines, doctors must navigate difficult, overlapping roles, balancing clinical knowledge with ...

In a 10-year study of postmenopausal women, tea consumption shows a small but significant benefit for bone mineral density, ...

Menopause hormone therapy neither increases nor decreases the risk for dementia or mild cognitive impairment in ...